Search
Research
Toll-like receptor 2 ligands inhibit Th2 responses to mite allergenThere is intense interest in the interaction between microbial compounds and allergy.
Research
Immunogenicity and boosting following a reduced number of doses of a Pneumococcal Conjugate Vaccine in infants and toddlersThe minimum number of doses of pneumococcal conjugate vaccine required for protection is not known. We studied the immunogenicity of a reduced schedule in...
News & Events
The Kids researchers help quantify global impact of life-saving vaccinesResearchers at The Kids Research Institute Australia have helped map the global impact of life saving vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation (EPI).
Research
Multidrug-resistant tuberculosis in Western Australia, 1998-2012Our objective was to describe the epidemiology, clinical features, health care resource use, treatment and outcomes of multidrug-resistant tuberculosis...
Research
A randomized phase I study of the safety and immunogenicityIn this study of healthy adults aged 50-85 and 18-24 years, SA3Ag elicited a rapid and robust immune response and was well tolerated, with no notable safety...
Research
Antibody persistence in Australian adolescents following meningococcal C conjugate vaccinationIn Australia, following the introduction of serogroup C meningococcal (MenC) conjugate vaccine for toddlers and catch-up immunization through adolescence,...
Research
What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and SingaporeWe performed a 2-week prospective survey of formal ID physician activities related to direct inpatient care, encompassing 53 hospitals throughout Australia,...
Research
The Impact of Pneumococcal Vaccination on Bacterial and Viral Pneumonia in Western Australian Children: Record Linkage Cohort Study of 469589 Births, 1996-2012We assessed the impact of PCV on all-cause and pathogen-specific pneumonia hospitalizations in Western Australian (WA) children aged 16 years.
Research
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)Pneumococcal disease (PD) remains a major health concern globally. In children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ and public health important serotypes 22F and 33F. This phase 3 study evaluated safety and immunogenicity of mixed PCV13/V114 regimens using a 3 + 1 dosing schedule when changing from PCV13 to V114 at doses 2, 3, or 4.